gallium nitrate

Trade name: ganite

Small moleculeapprovedOrphan Drug FDA

Approved

Jan 17, 1991

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents. — NCATS

Clinical trial activity

7 trials · 9 clinical orgs · 1 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 1994 (NCT00002578)

Timeline

1980s

  1. Dec 5, 1988

    Orphan Drug Designation

1990s

  1. Jan 17, 1991

    CheplaPharm — Earliest FDA Approval

  2. Jan 17, 1991

    CheplaPharm — Marketing Organization

  3. Jan 17, 1991

    CheplaPharm — NDA Organization

  4. Jan 1, 1994

    Earliest Phase 2 Sponsor(trial)

  5. Jan 1, 1995

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedPriority reviewJan 17, 1991

Chemistry & pharmacology

Loading structure…

SMILES

[Ga+3]
Mol. weight
69.723 g/mol
Chirality
Achiral Molecule
Inorganic
Yes
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • gallium nitrate
  • gallium nitrate
  • gallium nitrate
  • gallium nitrate
  • gallium nitrate
  • gallium nitrate
  • gallium nitrate
  • gallium nitrate
  • gallium nitrate
  • gallium nitrate, 67ga-labeled
  • gallium nitrate (anhydrous)
  • gallium nitrate (anhydrous)
  • gallium nitrate heptahydrate
  • ganite
  • ganite
  • ganite
  • ganite
  • ganite
  • nitric acid, gallium salt, anhydrate
  • nitric acid, gallium salt, anhydrate
  • nsc 15200

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04294043Phase 1May 1, 2020Cystic Fibrosis Foundation, University of Washington
NCT02354859Phase 2Mar 1, 2016Cystic Fibrosis Foundation Therapeutics, University of Washington
NCT01093521Phase 1Apr 1, 2010Cystic Fibrosis Foundation Therapeutics, University of Washington
NCT00836173Phase 2Jul 1, 2008Genta, Loyola University
NCT00054808Phase 2Jun 1, 2002Genta
NCT00002543Phase 1Feb 1, 1995Medical College of Wisconsin, National Cancer Institute (NCI)
NCT00002578Phase 2Aug 1, 1994Albany Medical College, National Cancer Institute (NCI), State University of New York, Buffalo
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of WashingtonAcademic/Hospital3322010
Cystic Fibrosis Foundation TherapeuticsAcademic/Hospital2022010
GentaFor profit2112002
National Cancer Institute (NCI)Government2021994
Albany Medical CollegeAcademic/Hospital1011994
Cystic Fibrosis FoundationAcademic/Hospital1012020
Loyola UniversityAcademic/Hospital1112008
Medical College of WisconsinAcademic/Hospital1111995
State University of New York, BuffaloAcademic/Hospital1111994
9 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
CheplaPharmFor profitMKTGJan 17, 1991
CheplaPharmFor profitNDAJan 17, 1991